Mechanism of Action: Orexin Receptor Antagonists

Drugs with Mechanism of Action: Orexin Receptor Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No	10,023,560
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-002	Apr 7, 2022		RX	Yes	Yes
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No	9,790,208		Y	Y
Idorsia	QUVIVIQ	daridorexant hydrochloride	TABLET;ORAL	214985-001	Apr 7, 2022		RX	Yes	No

Last updated: July 30, 2026

Orexin Receptor Antagonists: Market Dynamics and Patent Landscape (R&D, Generics, Biosimilar, and Licensing Outlook)

Orexin receptor antagonists used for insomnia are concentrated around a small set of approved actives: suvorexant, lemborexant, and daridorexant. The patent landscape is dominated by new molecular entities, polymorph/formulation IP, and method-of-use claims tied to insomnia and dosing regimens. Near-term generic risk varies by drug and by how completely the Orange Book estate is insulated with secondary patents. Market dynamics are driven by label positioning (sleep maintenance vs sleep onset), payer preference, formulary placement, and safety/tolerability perceptions rather than by large incremental efficacy spreads across classes.

The actionable picture for business planning is:

• Generic entry timing is primarily constrained by Orange Book-listed patent expirations and any exclusivity blocks (including NDA 30-month stay risk in Paragraph IV).
• Settlement vs litigation outcomes shape the effective launch window more than nominal expiration dates.
• Formulation and method-of-use patents are the key bottleneck for “easy-to-design-around” generics, especially for new dosing strengths and reformulations.

---

Which orexin receptor antagonists are approved for insomnia in the U.S., and what is their market share profile?

What drugs fall under the orexin receptor antagonist mechanism?

For insomnia, the approved small-molecule orexin pathway antagonists are:

• Suvorexant (Belsomra), orexin receptor antagonist (dual OX1R/OX2R).
• Lemborexant (Dayvigo), dual orexin receptor antagonist.
• Daridorexant (Quviviq), dual orexin receptor antagonist.

How does the market segment by dosing and label positioning?

Across dual orexin antagonists, marketing and formularies typically split along:

• Sleep maintenance vs sleep onset emphasis (label claims and prescribing patterns).
• Clinical comfort factors: next-morning impairment concerns, dosing flexibility, and perceived tolerability.

What drives payer and provider adoption?

Market uptake is generally determined by:

• formulary placement and step therapy,
• prescriber familiarity,
• rebate structures,
• and the practical convenience of dosing relative to bedtime routines.

---

What patents protect orexin receptor antagonists (suvorexant, lemborexant, daridorexant) in the U.S.?

How is the patent estate structured for dual orexin antagonists?

Patent protection typically clusters into four buckets:

1. Core compound patents (composition of matter).
2. Salts/polymorphs and crystalline forms (solid-state IP).
3. Formulations (tablet/capsule design, release profiles, excipient systems).
4. Method-of-use patents (insomnia diagnosis, sleep onset and sleep maintenance endpoints, dose-regimen claims, and specific patient populations in some estates).

Which claims tend to survive generic design-around attempts?

In practice, the patents most frequently asserted or that most strongly constrain generic launch are:

• formulation or solid-state patents covering specific manufacturing-relevant characteristics,
• secondary patents with claims that remain valid even if the active ingredient is identical,
• and method-of-use where Orange Book listing or FDA labeling alignment creates an enforceability hook.

What to expect from the Orange Book listing mechanics?

For each NDA, the Orange Book can include:

• patents listed for drug substance and drug product,
• and patents listed under method-of-use where claims correspond to the approved indication(s) and labeling.

---

When do orexin receptor antagonist patents expire, and what launch windows do they create?

How do expiration and exclusivity interact with generic timing?

Generic timing depends on two layers:

• Patent expiration (end of the last Orange Book patent covering the NDA, unless cleared by settlement or noninfringement).
• Exclusivity blocks (where applicable), which can delay FDA approval even when patents expire.

What produces the biggest deviation from “calendar math”?

Deviation drivers:

• Paragraph IV filings triggering the 30-month stay (if appropriate conditions are met).
• Settlement agreements that lock in earlier-or-later effective dates.
• Final court rulings determining whether asserted patents are invalid or not infringed.
• Continuations and patent term adjustments that shift effective expiration.

---

What Paragraph IV challenges exist for suvorexant, lemborexant, and daridorexant, and how do they affect market entry?

How do Paragraph IV challenges typically play out in this class?

In orexin antagonist portfolios, Paragraph IV challenges are generally litigated around:

• compound identity (often not disputed),
• formulation design-around (different excipients, particle size distributions, or solid-state forms),
• and method-of-use alignment with FDA-approved labeling.

What outcomes usually govern generic launch dates?

• a settlement that grants a “date certain” generic entry, or
• a court decision clearing the lead generic or narrowing asserted claims.

What investors and BD teams track

• the number of asserted patents per case,
• which patent families remain after early dismissals,
• and whether settlements cover multiple NDA strengths.

---

What is the Orange Book status of suvorexant, lemborexant, and daridorexant?

How to interpret Orange Book listings for risk scoring

Orange Book risk scoring for generic entry typically weights:

• last-to-expire patents (controlling launch),
• whether drug product patents are listed (harder for design-around),
• and whether method-of-use patents are listed (label-specific constraints).

What matters for litigation strategy

A generic applicant’s Paragraph IV narrative tends to focus on:

• invalidity or noninfringement of the controlling patents,
• and whether the ANDA carve-outs or labeling changes avoid infringement.

---

How strong is the patent estate for orexin receptor antagonists, and which patent families drive enforcement?

Strength factors

Patent estate strength is a function of:

• breadth of claims (composition and use),
• survival of secondary patents through prosecution and term adjustments,
• enforceability and litigation history,
• and whether formulations are tightly coupled to manufacturing methods.

What type of IP is most likely to be asserted

• formulation patents tied to the approved dosage form,
• solid-state and polymorph patents if the generic must match critical properties,
• and method-of-use patents if FDA labeling creates an infringement path.

Competitive implication

Strong estates tend to:

• reduce the number of true “at-risk” filers,
• increase settlement likelihood,
• and extend the pricing power of the originators.

---

What formulation and delivery-system patents protect orexin receptor antagonists?

Where generic companies face technical IP barriers

Even with identical actives, generics face barriers in:

• solid-state form matching (polymorph/crystal form),
• dissolution profiles,
• tablet hardness and disintegration characteristics,
• and manufacturing parameters that can correlate to claimed properties.

What patent claim themes appear in this space

For insomnia oral small molecules, formulation patents often target:

• excipient systems affecting dissolution,
• coating and release attributes,
• and controlled manufacturing attributes tied to specific claim limitations.

---

What method-of-use patents cover orexin receptor antagonists, and can generics avoid them by changing labels?

Do method-of-use patents create label constraints?

If method-of-use patents are listed and claims track approved indications, label changes can become:

• a viable carve-out, or
• a litigation flashpoint where the generic must show noninfringement given the ANDA labeling.

When label carve-outs fail in practice

Carve-outs tend to fail when:

• the remaining labeling still falls within the asserted claim language,
• or the court construes the claims broadly to cover the relevant dosing instruction.

---

Which companies hold and license the orexin antagonist patent assets, and what licensing patterns matter?

How originator portfolios are typically organized

Dual orexin antagonists are usually backed by:

• a lead assignee controlling core composition IP,
• separate assignees or licensees holding formulation or method-of-use families,
• and a portfolio approach that keeps at least one late-expiring patent category in place.

What licensing deals usually target

• formulation know-how and manufacturing rights,
• cross-licenses on platform solid-state technologies,
• or settlement-driven licenses that avoid continued litigation.

---

What patent litigation affects orexin receptor antagonists, and what settlements change the commercial timeline?

What litigation variables determine launch timing

• number of asserted patents,
• whether an early court ruling knocks out a major controlling patent,
• and whether settlements require development and launch milestones.

How settlements impact market dynamics

Settlements typically:

• reduce uncertainty for the branded manufacturer,
• allow generic companies to plan supply and commercialization,
• and can freeze entry for a defined period even after some patents expire.

---

What FDA regulatory pathways and exclusivity statuses influence approval timing for generics of orexin antagonists?

ANDA vs 505(b)(2) in this mechanism class

• ANDA is the typical route for generics using bioequivalence and identical formulations (when feasible).
• 505(b)(2) can be used for reformulations, alternative salts, or when bridging studies support differences, but it can introduce additional regulatory and IP complexity.

How the 30-month stay risk affects investment

For Paragraph IV ANDAs, the 30-month stay can:

• delay FDA approval,
• while litigation continues,
• creating a financing and supply planning risk window for generic entrants.

---

How do orexin receptor antagonist economics change around loss of exclusivity?

Pricing and volume dynamics after generic entry

When the last Orange Book patent clears:

• branded price usually faces downward pressure,
• volume shifts toward the lowest-cost approved alternatives,
• and payers may accelerate formulary switching.

What slows generic substitution

• existing payer contracts,
• physician switching costs,
• perceived safety or tolerability differences by product,
• and brand-level patient support programs.

---

How does suvorexant compare with lemborexant and daridorexant from a patent-risk and competition standpoint?

Patent-risk framework

A practical comparative lens:

• whether each NDA has a dense tail of secondary patents,
• whether drug product/formulation patents are controlling,
• and how litigation and settlements have historically shaped effective launch dates.

Competitive implications

• If one product has more late-expiring formulation or method-of-use patents, it tends to retain pricing more effectively post-expiration.
• If a product has a thinner tail, the generic pathway can accelerate.

---

Key Takeaways

• Orexin receptor antagonists for insomnia are a compact, IP-dense segment where secondary patents (formulation and method-of-use) drive the real generic launch calendar more than headline composition-of-matter expirations.
• Market dynamics are shaped by payer formulary decisions, label positioning, and tolerability perceptions, while patent events determine the timing of effective competitive disruption.
• For R&D and BD teams, controlling factors for generic risk are:
  • Orange Book last-to-expire patents,
  • strength and enforceability of drug product/formulation claims,
  • and whether Paragraph IV challenges and settlements set a date-certain entry.

---

FAQs

1. Which orexin receptor antagonist has the latest Orange Book “last-to-expire” patent position in the U.S.?
2. Do method-of-use patents for dual orexin antagonists require label-level carve-outs to avoid infringement by generics?
3. How do polymorph and solid-state formulation patents affect ANDA design-around strategies for suvorexant, lemborexant, or daridorexant?
4. What settlement terms most commonly determine the effective launch date after Paragraph IV litigation in the insomnia drug market?
5. How do FDA exclusivity and the 30-month stay interact with patent expirations for generic entry of orexin antagonists?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA. Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
3. FDA. ANDA Disputes and Litigation; 30-Month Stay (Hatch-Waxman framework materials). U.S. Food and Drug Administration. https://www.fda.gov/